Rupal S. Bhatt

2.7k total citations
84 papers, 1.9k citations indexed

About

Rupal S. Bhatt is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Rupal S. Bhatt has authored 84 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 41 papers in Molecular Biology and 30 papers in Cancer Research. Recurrent topics in Rupal S. Bhatt's work include Renal cell carcinoma treatment (51 papers), Renal and related cancers (23 papers) and Cancer Genomics and Diagnostics (14 papers). Rupal S. Bhatt is often cited by papers focused on Renal cell carcinoma treatment (51 papers), Renal and related cancers (23 papers) and Cancer Genomics and Diagnostics (14 papers). Rupal S. Bhatt collaborates with scholars based in United States, Israel and Canada. Rupal S. Bhatt's co-authors include Michael B. Atkins, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Mary E. Hatten, Toshifumi Tomoda, Vikas P. Sukhatme, David C. Alsop, Marcella Callea and Jiaxi Song and has published in prestigious journals such as Journal of Clinical Investigation, Neuron and Journal of Clinical Oncology.

In The Last Decade

Rupal S. Bhatt

83 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rupal S. Bhatt United States	25	917	848	652	553	222	84	1.9k
Toshi Menju Japan	23	642 0.7×	966 1.1×	653 1.0×	386 0.7×	132 0.6×	113	2.0k
Luigi Formisano Italy	25	1.1k 1.2×	772 0.9×	1.1k 1.7×	494 0.9×	165 0.7×	73	2.2k
Antonio Marchetti Italy	23	929 1.0×	715 0.8×	878 1.3×	594 1.1×	86 0.4×	39	1.8k
Jeanine M.L. Roodhart Netherlands	22	1.0k 1.1×	399 0.5×	1.3k 1.9×	646 1.2×	285 1.3×	85	2.3k
Jane Kendrew United Kingdom	22	1.5k 1.7×	638 0.8×	1.1k 1.7×	561 1.0×	128 0.6×	33	2.7k
Tobias Zellweger Switzerland	26	1.2k 1.3×	823 1.0×	1.1k 1.7×	709 1.3×	251 1.1×	51	2.4k
Gyula Ostoros Hungary	21	773 0.8×	1.1k 1.3×	1.2k 1.9×	691 1.2×	141 0.6×	62	2.2k
Kazuhiko Shien Japan	23	955 1.0×	863 1.0×	885 1.4×	563 1.0×	173 0.8×	121	2.0k
Kenneth F. Grossmann United States	27	997 1.1×	517 0.6×	1.2k 1.9×	273 0.5×	435 2.0×	95	2.3k
Sebastian Oltean United Kingdom	25	2.0k 2.2×	454 0.5×	733 1.1×	753 1.4×	187 0.8×	50	2.8k

Countries citing papers authored by Rupal S. Bhatt

Since Specialization

Citations

This map shows the geographic impact of Rupal S. Bhatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rupal S. Bhatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rupal S. Bhatt more than expected).

Fields of papers citing papers by Rupal S. Bhatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rupal S. Bhatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rupal S. Bhatt. The network helps show where Rupal S. Bhatt may publish in the future.

Co-authorship network of co-authors of Rupal S. Bhatt

This figure shows the co-authorship network connecting the top 25 collaborators of Rupal S. Bhatt. A scholar is included among the top collaborators of Rupal S. Bhatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rupal S. Bhatt. Rupal S. Bhatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Wenxin, Sai Vikram Vemula, Robert J. Motzer, et al.. (2025). Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.. Journal of Clinical Oncology. 43(5_suppl). 437–437. 2 indexed citations

Xu, Weidong, Valérie Gaborieau, Samuel M. Niman, et al.. (2022). 1471P Plasma KIM-1 for preoperative identification and risk stratification of renal cell carcinoma. Annals of Oncology. 33. S1219–S1219.

McKay, Rana R., Lucia Kwak, Jett Crowdis, et al.. (2021). Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clinical Cancer Research. 27(13). 3610–3619. 21 indexed citations

Xu, Wenxin, Mäneka Puligandla, Brian Halbert, et al.. (2021). Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). Clinical Cancer Research. 27(12). 3397–3403. 26 indexed citations

Bhatt, Rupal S., Kathleen M. Mahoney, Samuel S. Freeman, et al.. (2020). KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunology Research. 9(2). 156–169. 80 indexed citations

Tsai, Leo L., Rupal S. Bhatt, Opeyemi A. Jegede, et al.. (2020). Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. Radiology. 298(2). 332–340. 10 indexed citations

Fischl, Anthony S., Xiaoen Wang, Beverly L. Falcón, et al.. (2019). Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition. Molecular Cancer Therapeutics. 18(4). 856–867. 16 indexed citations

Xu, Wenxin, Mäneka Puligandla, Judith Manola, et al.. (2019). Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clinical Cancer Research. 25(20). 6098–6106. 11 indexed citations

Melms, Johannes C., Rohit Thummalapalli, Huihui Ye, et al.. (2018). Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic. Journal for ImmunoTherapy of Cancer. 6(1). 89–89. 10 indexed citations

10.

Hu, Junhui, Shiruyeh Schokrpur, Maani M. Archang, et al.. (2018). A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. Molecular Therapy — Methods & Clinical Development. 9. 203–210. 31 indexed citations

11.

Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565. 21 indexed citations

12.

Mahoney, Kathleen M., Susanna Jacobus, Rupal S. Bhatt, et al.. (2016). Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 14(4). 304–313.e6. 9 indexed citations

13.

Wang, Xiaoen, Andrea J. Bullock, Marcella Callea, et al.. (2015). Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clinical Cancer Research. 21(8). 1925–1934. 67 indexed citations

14.

Callea, Marcella, Laurence Albigès, Mamta Gupta, et al.. (2015). Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research. 3(10). 1158–1164. 266 indexed citations

15.

Beddy, Peter, Elizabeth M. Genega, Long Ngo, et al.. (2013). Tumor Necrosis on Magnetic Resonance Imaging Correlates With Aggressive Histology and Disease Progression in Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer. 12(1). 55–62. 39 indexed citations

16.

Bhatt, Rupal S., Xiaoen Wang, Liang Zhang, et al.. (2010). Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling. Molecular Cancer Therapeutics. 9(10). 2793–2802. 48 indexed citations

17.

Bhatt, Rupal S., Jaime R. Merchan, Robert Parker, et al.. (2010). A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 116(7). 1751–1756. 57 indexed citations

18.

Bhatt, Rupal S., Xiaoen Wang, Liang Zhang, et al.. (2009). Abstract #153: Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models. Cancer Research. 69. 153–153. 1 indexed citations

19.

Bhatt, Rupal S. & Glenn J. Bubley. (2008). The Challenge of Herbal Therapies for Prostate Cancer. Clinical Cancer Research. 14(23). 7581–7582. 3 indexed citations

20.

Bhatt, Rupal S., Daniel M. Landis, Michael Zimmer, et al.. (2008). Hypoxia‐inducible factor‐2α: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. British Journal of Urology. 102(3). 358–363. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact